Author Archives: Huy Ly

NEW YORK (GenomeWeb) – At a recent conference, personalized medicine newcomer Pairnomix shared the first case report demonstrating its exhaustive methodology to functionally study and determine treatments for patients with novel or poorly understood genetic mutations. Launched about a year ago, the firm set out with a unique approach to personalized medicine — in essence, […]

Findings Presented at the 70th Annual Meeting of the American Epilepsy Society Houston, TX – December 3, 2016 – Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today announced that findings from its first case study of an individualized approach to the identification […]

MAPLE GROVE, Minn., Oct. 7, 2016 /PRNewswire/ – Pairnomix, LLC, a genetic research company, today announced that CEO, Matthew Fox will present at KCNQ2 Cure’s 2016 Family and Professional Summit, October 7-9, 2016 in Silver Spring, MD. This three-day event is designed to unite all groups committed to improving the lives of those with KCNQ2 […]

Helping Patients Understand Their Rare Genetic Mutation; Helping Physicians Identify Potential New Treatment Options Maple Grove, MN – September 27, 2016 – Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today reported on the successful launch of its unique characterization and drug screening […]

Pairnomix’ efforts to bring precision medicine to the epilepsy community was featured in the April edition of the American Journal of Medical Genetics Part A. The article explores the company’s mission to provide personalized genetic research to an underserved market, namely individuals diagnosed with epilepsy due to identified, causative genetic mutations. Some researchers believe that […]

Pairnomix CEO Matthew Fox was among the leading decision-makers included in this year’s Epilepsy Foundation Pipeline Conference. Fox presented an overview of how the personalized genetic research company is helping epilepsy patients better understand their disorder.

Patient-Empowered Precision Medicine Alliance (PEPMA) Aims to Match Patients and Therapies Maple Grove, MN – February 25, 2016 – The White House today announced the creation of the Patient-Empowered Precision Medicine Alliance (PEPMA), which Pairnomix, LLC has joined alongside researchers and collaborators from Harvard Medical School, the University of Utah, Boston Children’s Hospital, and Recursion […]

A 2015 Medscape Medical News article from the American Epilepsy Society 69th Annual Meeting highlighted the company’s efforts to pair rare disease genomics and advanced analytics to help epilepsy patients better understand their disorder. CEO Matthew Fox explained how, within a laboratory setting, Pairnomix models and characterizes a known mutation, tests compounds on it and […]

NEW YORK (GenomeWeb) – Seeking to fill an unmet need, newly launched firm Pairnomix will begin offering a commercial service this January consisting of comprehensive follow-up in vitro modeling and scientific research for individuals who have an identified, but ill-understood genetic variant in the context of genetically mediated rare disorders, starting with epilepsy. The company […]

Denver, CO – December 7, 2015 – KCNQ2 Cure Alliance today announced that it has entered into a collaboration with Pairnomix, a new genetic research company, to further explore genetic mutations in KCNQ2 epileptic encephalopathy with the goal of identifying more effective and more accurately targeted therapies. Approximately 200 people worldwide have been diagnosed with […]